Several monoclonal antibodies (mAb) are in development for the treatment of uncontrolled asthma. Network meta-analysis (NMA) will become unavoidable to compare effectiveness of these products. It could only be performed if studies define outcomes similarly. The objective of this research is to review the consistency of exacerbation definition used in clinical trials of mAb.